Verrica Pharmaceuticals (VRCA) Interest & Investment Income (2018 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Interest & Investment Income of $201000.0 for Q1 2026, down 40.36% year-over-year from $337000.0 in Q1 2025, and down 1.95% quarter-over-quarter from $205000.0 in Q4 2025.
Verrica Pharmaceuticals (VRCA) Interest & Investment Income (2018 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Interest & Investment Income history runs 9 years deep, the most recent figure standing at $201000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 40.36% year-over-year to $201000.0; the TTM figure through Mar 2026 stood at $793000.0 (down 31.4% YoY), while the FY2025 annual figure was $929000.0, down 34.44% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $201000.0, down from $205000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $822000.0 in Q3 2023, with the low at $20000.0 in Q2 2022.
- The 5-year median for Interest & Investment Income is $228000.0 (2025), against an average of $339000.0.
- The sharpest annual moves came in 2023 and 2024: Interest & Investment Income jumped 3030.0% in 2023, then tumbled 74.12% in 2024.
- Verrica Pharmaceuticals' Interest & Investment Income stood at $286000.0 in 2022, then soared by 176.92% to $792000.0 in 2023, then sank by 74.12% to $205000.0 in 2024, then changed by 0.0% to $205000.0 in 2025, then fell by 1.95% to $201000.0 in 2026.
- Business Quant data shows VRCA's Interest & Investment Income at $201000.0 in Q1 2026, $205000.0 in Q4 2025, and $159000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | 111,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 111,000.00 |
| Mar 31, 2026 | 201,000.00 |
| Dec 31, 2025 | 205,000.00 |
| Sep 30, 2025 | 159,000.00 |
| Jun 30, 2025 | 228,000.00 |
| Mar 31, 2025 | 337,000.00 |
| Dec 31, 2024 | 205,000.00 |
| Sep 30, 2024 | 221,000.00 |
| Jun 30, 2024 | 393,000.00 |
| Mar 31, 2024 | 598,000.00 |
| Dec 31, 2023 | 792,000.00 |
| Sep 30, 2023 | 822,000.00 |
| Jun 30, 2023 | 626,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Dec 31, 2022 | 286,000.00 |
| Sep 30, 2022 | 148,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Mar 31, 2022 | 22,000.00 |
| Dec 31, 2021 | 27,000.00 |
| Sep 30, 2021 | 31,000.00 |